Relapsed and/or refractory (R/R) pediatric acute leukemia carries a dismal prognosis, largely driven by chemoresistance to conventional salvage therapy. The BH3-mimetic venetoclax, combined with chemotherapy or hypomethylating agents, has demonstrated efficacy in small clinical trials. However, data on its role as a br...
Katherine S. Colman, D. Meyran, V. Malalasekera et al.· Pediatric Blood & Cancer· 0 citations
Single-cell RNA-sequencing resolves cellular states in exquisite detail. Yet oncogenic gene fusions, key drivers in 16.5% of malignancies and ∼50-70% of acute lymphoblastic leukaemia (ALL) cases, remain largely invisible at this resolution. This leaves a fundamental gap in understanding cancer biology. We close it with...
Jovana Maksimovic, Victoria Streeton-Cook, Calandra V. Grima et al.· bioRxiv· 0 citations
The role of comprehensive genomic profiling for therapeutic decision-making is established in high-risk pediatric cancers, but its utility in rare and diagnostically challenging tumors is unclear. Here we report 123 non-high-risk patients enrolled in the Australian ZERO Childhood Cancer Program for diagnostic uncertain...
David S. Ziegler, A. Sullivan, Dong-Anh Khuong-Quang et al.· Research Square· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.